文献速递妇产影像US

聚焦超声治疗未孕女性高危人乳头瘤病毒感染相关宫颈上皮内瘤变2级的疗效与安全性:一项回顾性研究

Efficacy and Safety of Focused Ultrasound Treatment for High-risk Human Papillomavirus Infection-related Cervical Intraepithelial Neoplasia Grade 2 in Nulligravidae Women: A Retrospective Study.
PubMed 文献 · Ultrasound Med Biol · 2024-11-23

本回顾性研究纳入31例18-35岁未孕、组织学确诊为CIN2且伴HR-HPV感染的患者,接受聚焦超声治疗。治疗后6个月完全病理缓解率为70.96%,部分缓解率为25.80%;HPV清除率6个月为35.48%,12个月为71.49%。作者认为聚焦超声在35岁以下未产女性CIN2中表现出良好的安全性和疗效,其对生育力的获益有待进一步研究。

要点

  • 聚焦超声治疗后6个月完全病理缓解22/31例(70.96%),部分缓解8/31例(25.80%)。
  • HPV清除率6个月为35.48%,12个月升至71.49%。
  • 最常见不良事件为中度下腹痛和阴道分泌物增多。

核心结论

  • 聚焦超声在35岁以下未产女性CIN2中表现出良好的安全性和疗效,其对生育力的获益有待进一步研究。

研究设计与样本

  • 回顾性研究,共纳入31例18-35岁、组织学确诊CIN2且伴HR-HPV感染的未孕患者,均接受聚焦超声治疗,治疗后6个月和12个月随访评估组织病理学应答、HPV感染清除及治疗相关不良事件。

诊断标准与关键数值

  • 治疗后6个月完全病理缓解22/31例(70.96%),部分缓解8/31例(25.80%)。
  • 从病理诊断到治疗后达到完全缓解或部分缓解的平均时间为214.36 ± 24.31天(范围186-270天)。
  • HPV基线清除率6个月为35.48%,12个月为71.49%。
  • 有妊娠意愿的患者中成功妊娠率为57.14%,共8次分娩。

局限性

  • 原文结论指出聚焦超声对生育力的获益有待进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: This retrospective study aimed to investigate the efficacy and safety of focused ultrasound (FU) treatment for high-risk human papillomavirus (HR-HPV) infection-related cervical intraepithelial neoplasia grade 2 (CIN2) in nulligravidae under 35 y old, while also assessing pregnancy outcomes post-treatment.

METHODS: Nulligravid patients aged 18-35 y with histologically confirmed CIN2 and HR-HPV infection were included in the study. We collected demographics, pertinent medical history, HPV genotypes and cervical length at baseline. Follow-up evaluations were conducted at 6- and 12-mo intervals post-treatment to assess histopathological response, HPV infection clearance and adverse events related to treatment.

RESULTS: A total of 31 eligible patients were recruited and underwent FU treatment. At the 6-mo follow-up, complete pathologic response was observed in 22 out of 31 patients (70.96%), while partial response was seen in eight out of 31 patients (25.80%). The average duration from pathological diagnosis to achieving either a complete response or partial response after treatment was 214.36 ± 24.31 (186-270) d. The baseline remission rate for HPV was 35.48% at 6 mo, increasing to 71.49% at 12 mo. Moderate lower abdominal pain and increased vaginal discharge were the most frequent adverse events. Among the patients desiring pregnancy, the successful pregnancy rate was 57.14%, resulting in eight deliveries.

CONCLUSION: FU demonstrated a favorable safety profile and efficacy in nulliparous females under 35 y old with CIN2, and its benefits for fertility warrant further investigation.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Zhang M, Jiang H, Chen L, et al. Efficacy and Safety of Focused Ultrasound Treatment for High-risk Human Papillomavirus Infection-related Cervical Intraepithelial Neoplasia Grade 2 in Nulligravidae Women: A Retrospective Study. Ultrasound Med Biol. 2024. PMID: 39581821. doi:10.1016/j.ultrasmedbio.2024.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。